In March 2015, the Journal of Cutaneous Pathology published a study regarding a novel diagnostic test for melanoma. Using quantitative RT-PCR targeting 23 preselected genes (MyPath Melanoma, Myriad Genetics), biopsy samples from a variety of melanocytic skin lesions (464 lesions in a training set and 437 lesions in a separate validation set) were analyzed.
MRV Research
Promising Immunotherapy Combination for Patients with Untreated Melanoma Revealed in Study
A new study recently published in The New England Journal of Medicine revealed that a specific combination of immunotherapies yielded promising results in patients with untreated advanced melanoma. The study was led by researchers at the Ludwig Center at Memorial Sloan Kettering Cancer Center, the Weill Cornell Medical College, New York and the Dana–Farber Cancer Institute, Boston and is entitled “Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma.”
BMS hails Opdivo and Yervoy combo in melanoma
New PD-1 therapy shines against the world’s first immunotherapy for skin cancer.
Combining Bristol-Myers Squibb’s PD-1 inhibitor Opdivo and older melanoma drug Yervoy boosted progression-free survival (PFS) compared to Yervoy alone in a clinical trial.
Bristol-Myers: 2 Cancer Drugs Beat 1 Against Melanoma
Giving patients with advanced melanoma two Bristol-Myers drugs that work differently held the deadly skin cancer at bay far longer than just one, though the combination’s considerable increase in serious side effects raises concerns about how much patients can endure.